Silexion Therapeutics implements 1-for-15 reverse stock split

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced a 1-for-15 reverse stock split of its ordinary shares, effective after market close on July 28, 2025. Trading on a split-adjusted basis will begin July 29, 2025, on the Nasdaq Capital Market under the existing ticker symbol SLXN.

The biotechnology company stated the reverse split is intended to help maintain compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Every 15 ordinary shares will be combined into one share, with the par value increasing from $0.0009 to $0.0135 per share.

Shareholders holding shares in book-entry form or through brokers will not need to take action, as adjustments will be made automatically. A new CUSIP number will be assigned to the post-split shares, and no fractional shares will be issued.

"This reverse share split reflects Silexion's unwavering commitment to maintaining our Nasdaq listing and strengthening our foundation for future growth," said Ilan Hadar, Chairman and CEO.

The company develops RNA interference therapies for KRAS-driven cancers. Its first-generation product LODER has shown results in a Phase 2 trial for non-resectable pancreatic cancer, while its next-generation candidate SIL-204 is in preclinical development.

The reverse split is designed to address share price volatility and support the company's ability to conduct equity financings, according to the press release statement.

You May Also Be Interested In

• Trump: Iran Will Pay For US Forces Killings Many Times Over
• Sheba Medical Center to trial Valion Bio's Entolimod in cancer patients
• H.B. Fuller refinances credit facilities, extends maturity to 2031